January 2, 2013
In December 2012, we hosted a roundtable discussion focused on our activities and progress with our conjugate platform to deliver RNAi therapeutics subcutaneously. The roundtable included a review of our two leading conjugate programs: ALN-TTRsc for the treatment of transthyretin mediated amyloidosis, and ALN-AT3 for the treatment of hemophilia and other bleeding disorders.
Listen to the replay View the presentation (254 KB PDF)
May 31, 2011
In May 2011, we held a roundtable discussion focused on our ALN-VSP program; specifically, the important proof of mechanism data that we had reported on earlier in the year.
ALN-VSP RNAi Roundtable webcast, May 2011 (65 MB MP3) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Read our press releaseJuly 22, 2010
Following the initiation of our Phase I clinical study with ALN-TTR01 in July 2010, we hosted a virtual RNAi Roundtable to provide investors with a full overview of our ALN-TTR program.
ALN-TTR RNAi Roundtable webcast, July 2010 (61.9 MB MP3) ALN-TTR RNAi Roundtable, July 2010 (1.0 MB PPT)March 4, 2010
In March 2010, we hosted an RNAi Roundtable where Alnylam’s Dr. Akin Akinc, Associate Director of Research, provided an update on the latest advances around the delivery of RNAi therapeutics.
Delivery RNAi Roundtable webcast, March 2010 (64.4 MB MP3) Delivery RNAi Roundtable, March 2010 (3.2 MB PPT)September 24, 2009
In September 2009, we hosted an RNAi Roundtable to provide a deep dive into our RNAi Lead Discovery, or RLD, efforts.
RLD RNAi Roundtable webcast, September 2009 (47.4 MB MP3) RLD RNAi Roundtable, September 2009 (2.1MB PPT)July 30, 2009
In July 2009, we held an RNAi Roundtable focused on our ALN-RSV program.
ALN-RSV RNAi Roundtable, July 2009 (1.3MB PPT)
